| Identification | Back Directory | [Name]
DV 7028 hydrochloride | [CAS]
133364-62-2 | [Synonyms]
DV 7028 hydrochloride
3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione hydrochloride | [Molecular Formula]
C21H26ClFN4O3 | [MDL Number]
MFCD00897569 | [MOL File]
133364-62-2.mol | [Molecular Weight]
436.91 |
| Chemical Properties | Back Directory | [storage temp. ]
Desiccate at RT | [solubility ]
Soluble to 10 mM in water with gentle warming and to 10 mM in DMSO with gentle warming | [form ]
Powder |
| Hazard Information | Back Directory | [Description]
Selective 5-HT2A receptor antagonist (Ki = 22 nM for at 5-HT2 receptors). Exhibits no affinity for 5-HT1A, 5-HT1B or 5-HT1D receptors. Inhibits collagen-induced serotonin secretion and platelet aggregation; displays no effect on serotonin uptake by platelets. Shown to inhibit arterial thrombus formation, but not venous thrombosis, in rat models. | [Uses]
DV-7028 is a selective 5-hydroxytryptamine2 (5-HT2) receptor antagonist[1]. | [in vivo]
DV-7028 (0.1 mg/kg, intravenously) reduced the frequency of cyclic flow reductions by 77% in dog and improved the nadir of coronary blood flow velocity that indicated the severity of cyclic flow reductions [1]. | [IC 50]
5-HT2 Receptor | [storage]
Desiccate at RT | [References]
[1] Tanaka T, et al. Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs. Cardiovasc Res. 1993 Jul;27(7):1374-9. DOI:10.1093/cvr/27.7.1374 |
|
|